Clinical trial
A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate
NCT00284973 · Shanghai Wanxing Bio-Pharmaceutical Co. Ltd., Industry · Completed
Key facts
| NCT number | NCT00284973 |
|---|---|
| Title | A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate |
| Official title | Ph-1 Double-Blind Randomized Control Study-Evaluate Safety & Immunogenicity of Wanxing Bio-Pharmaceuticals AMA-1/MSP-1 Recombinant Malaria Vaccine (PfCP-2.9) Adj. w/ Montanide ISA 720 Compared to Montanide ISA 720 Alone in Adult Volunteers |
| Lead sponsor | Shanghai Wanxing Bio-Pharmaceutical Co. Ltd., Industry |
| Collaborators | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Second Military Medical University World Health Organization PATH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prophylaxis Against Plasmodium Falciparum Malaria |
| Intervention type | Biological |
| Interventions | Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720 |
| Enrollment | 70 |
| Start date | Jan 1, 2006 |
| First posted | Feb 1, 2006 |
| Last update posted | Apr 14, 2015 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: